skinny.

Latest / Lymphoma Hub

SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In this interview, Paolo Ghia shares data from Arm D of the phase III SEQUOIA (NCT03336333) study of patients with del(17p) and/or pathogenic TP53 mutation treated with zanubrutinib in combination with venetoclax. Ghia covers key preliminary…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.